Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Varcode Forms Strategic Partnership with PL Developments to Build Cold Chain Monitoring into Pharma Manufacturing, Packaging, Distribution

CHICAGO – January 12, 2020 – Varcode™, maker of digital, time- and temperature-sensitive supply chain solutions, today announced it has formed a strategic partnership with PL Developments (PLD) to enhance the scale and availability of Varcode’s cold chain monitoring technology.   Under the agreement, amongst other things, PLD will assemble and apply Varcode “Smart Tags” to products onsite and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Varcode Forms Strategic Partnership with PL Developments to Build Cold Chain Monitoring into Pharma Manufacturing, Packaging, Distribution

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

CHICAGO – January 12, 2020 – Varcode™, maker of digital, time- and temperature-sensitive supply chain solutions, today announced it has formed a strategic partnership with PL Developments (PLD) to enhance the scale and availability of Varcode’s cold chain monitoring technology.

Under the agreement, amongst other things, PLD will assemble and apply Varcode “Smart Tags” to products onsite and inline as they roll down the assembly line.

With more than 2,000 employees and more than 1 million square feet of state-of-the art pharmaceutical facilities in the United States, PLD manufactures, packages, and distributes more than 300 healthcare products for leading retailers and pharmaceutical companies in the U.S. and around the globe.

“We believe this represents a significant milestone for cold chain monitoring and protection. This is an industry first, being able to apply digital time and temperature monitoring at the point of manufacturing. The implications for scale and efficiency are enormous,” said Joe Battoe, CEO of Varcode.

Mr. Battoe noted that the strategic partnership avails Varcode of extensive, relevant support services from PLD, including supply chain, quality assurance, compliance management and more.

“PLD’s mission is to provide our customers and consumers with quality and affordable healthcare products,” said Evan Singer, president of PLD. “Varcode’s innovative and proprietary technology platform allows all stakeholders, at a fraction of the cost of alternative temperature tracking solutions, to confirm that products have been handled within required ranges throughout the supply chain.”

Varcode’s digital Smart Tags dynamically change based on customized time and temperature parameters, tracking product safety and efficacy throughout the supply chain. The barcoded Smart Tags are scanned by any fixed or hand-held scanner as well as smartphone. The labels use a combination of precisely tuned chemicals and a uniquely printed layer to capture cumulative temperature variances when and where they occur and create a permanent, irreversible digital record securing stored in the cloud.

“Our partnership with Varcode aligns our two companies’ unique capabilities to drive industry innovation and long-term success,” said Mr. Singer. “By combining PLD’s experience, resources, scale and operational efficiencies with Varcode’s patented technologies and agile development capabilities, we jointly expand our abilities to serve the exacting needs of pharma brands and their customers.”

Varcode and PLD have already begun co-development and anticipate having onsite and inline capabilities available soon to support the mass distribution of cold chain required products, including Covid-19 vaccines.

About PL Developments

Founded in 1988, PL Developments is a top manufacturer, packager and distributor of store-brand OTC pharmaceutical and consumer healthcare products. PLD is a U.S. based manufacturer, packager and distributor of pharmaceutical products, with a focus on serving US retailers in their store brands. Operating 7 sites and offering more than 300 unique products across various dosage forms and therapeutic categories, PLD is a leading supply of over-the-counter pharmaceutical products. For more information, visit: www.pldevelopments.com

About Varcode™

The name Varcode is short for variable barcode. Varcode is the developer of patented technology to enable scannable barcodes to dynamically change based on prescribed time and temperature threshold conditions. These smart barcode tags can be scanned via any fixed or handheld scanner, smartphone, or tablet to capture location- and time-sensitive temperature data which are then uploaded to Varcode’s cloud-based, blockchain-enabled management system. The system provides real-time alerts via SMS and email to stakeholders as well as providing comprehensive track and trace provenance for temperature sensitive products such as perishable food for safety, compliance and sustainability purposes. For additional information visit: www.Varcode.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512